Daiwa Securities Group Inc. Sells 6,905 Shares of Repligen Co. (NASDAQ:RGEN)

Daiwa Securities Group Inc. lowered its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 27.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,580 shares of the biotechnology company’s stock after selling 6,905 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Repligen were worth $2,765,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in RGEN. Cerity Partners LLC lifted its holdings in shares of Repligen by 90.0% in the 3rd quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock valued at $825,000 after acquiring an additional 2,625 shares during the last quarter. Nicolet Advisory Services LLC boosted its holdings in Repligen by 6.6% during the 3rd quarter. Nicolet Advisory Services LLC now owns 3,254 shares of the biotechnology company’s stock valued at $452,000 after acquiring an additional 201 shares during the period. Champlain Investment Partners LLC grew its position in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares during the last quarter. Icon Wealth Advisors LLC increased its stake in Repligen by 2,081.6% in the third quarter. Icon Wealth Advisors LLC now owns 32,571 shares of the biotechnology company’s stock worth $4,847,000 after purchasing an additional 31,078 shares during the period. Finally, Raymond James Trust N.A. lifted its position in shares of Repligen by 20.9% during the third quarter. Raymond James Trust N.A. now owns 2,750 shares of the biotechnology company’s stock worth $409,000 after purchasing an additional 475 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of Repligen stock opened at $149.99 on Thursday. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The company has a 50-day simple moving average of $140.58 and a two-hundred day simple moving average of $142.84. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The company has a market capitalization of $8.40 billion, a PE ratio of -405.37, a P/E/G ratio of 4.40 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 earnings per share. Research analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of a number of research analyst reports. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company started coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.